Lithium orotate for early-stage Alzheimer's disease
Part of Brain & nervous system clinical trials.
This study tests whether a low-dose lithium supplement, called lithium orotate, can safely stabilize or improve thinking and memory in people with mild Alzheimer's disease. It also looks at whether the drug affects markers of the disease in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of mild Alzheimer's disease confirmed by a biomarker test (for example, a PET scan or spinal fluid test for amyloid or tau).
- Your dementia is mild, measured by a standard scale (CDR of 1 or less, or QDRS of 8 or less).
- You are medically stable and can attend study visits and complete tests.
- If you take medications for mood, anxiety, or other mental health conditions, your doses have been stable for at least 4 weeks.
- You are not currently taking anti-amyloid antibody therapy (like aducanumab or lecanemab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a near-infrared light therapy device can help improve memory and thinking in people with mild to moderate Alzheimer's disease. It involves daily treatment sessions with the device, and a study partner must be available to help with treatment.
This study tests whether two natural plant compounds, oleanolic acid and erythrodiol, can protect brain cells and slow down early memory loss in people who have signs of Alzheimer's disease but are still functioning well in daily life.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This trial tests a new probiotic (Lactococcus lactis CKDB001) to see if it can slow memory loss in people with early Alzheimer's. It’s a 12-week study that requires a positive amyloid PET scan and allows mild to moderate symptoms.
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.